67 related articles for article (PubMed ID: 38487005)
1. Aerosolized immunotherapeutic nanoparticle inhalation potentiates PD-L1 blockade for locally advanced lung cancer.
Liu Y; Crowe WN; Wang L; Petty WJ; Habib AA; Zhao D
Nano Res; 2023 Apr; 16(4):5300-5310. PubMed ID: 37228440
[TBL] [Abstract][Full Text] [Related]
2. Hsc70 promotes anti-tumor immunity by targeting PD-L1 for lysosomal degradation.
Xu X; Xie T; Zhou M; Sun Y; Wang F; Tian Y; Chen Z; Xie Y; Wu R; Cen X; Zhou J; Hou T; Zhang L; Huang C; Zhao Q; Wang D; Xia H
Nat Commun; 2024 May; 15(1):4237. PubMed ID: 38762492
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Immunosuppressive Tumors by Polymer-Assisted Inductions of Immunogenic Cell Death and Multivalent PD-L1 Crosslinking.
Li L; Li Y; Yang CH; Radford DC; Wang J; Janát-Amsbury M; Kopeček J; Yang J
Adv Funct Mater; 2020 Mar; 30(12):. PubMed ID: 33071706
[TBL] [Abstract][Full Text] [Related]
4. Cancer Cell-Selective PD-L1 Inhibition via a DNA Safety Catch to Enhance Immunotherapy Specificity.
Bi S; Chen W; Fang Y; Shen J; Zhang Q; Guo H; Ju H; Liu Y
Angew Chem Int Ed Engl; 2024 May; 63(20):e202402522. PubMed ID: 38421189
[TBL] [Abstract][Full Text] [Related]
5. Polymer-based antibody mimetics (iBodies) target human PD-L1 and function as a potent immune checkpoint blocker.
Zamani MR; Hadzima M; Blažková K; Šubr V; Ormsby T; Celis-Gutierrez J; Malissen B; Kostka L; Etrych T; Šácha P; Konvalinka J
J Biol Chem; 2024 Apr; 300(6):107325. PubMed ID: 38685532
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a Trispecific PD-L1 Blocking Antibody That Exhibits EGFR-Conditional 4-1BB Agonist Activity.
Rubio-Pérez L; Frago S; Compte M; Navarro R; Harwood SL; Lázaro-Gorines R; Gómez-Rosel M; Hangiu O; Silva-Pilipich N; Vanrell L; Smerdou C; Álvarez-Vallina L
Antibodies (Basel); 2024 Apr; 13(2):. PubMed ID: 38804302
[TBL] [Abstract][Full Text] [Related]
7. Sulforaphane impaired immune checkpoint blockade therapy through activating ΔNP63α/PD-L1 axis in gastric cancer.
Zhang Q; Yang C; Ma Z; Ye L; Wu Y; Zhong C; Shi Y; Zhu M
Mol Carcinog; 2024 May; ():. PubMed ID: 38780147
[TBL] [Abstract][Full Text] [Related]
8. Mathematical modeling and analysis of cancer treatment with radiation and anti-PD-L1.
Liao KL; Wieler AJ; Gascon PML
Math Biosci; 2024 May; 374():109218. PubMed ID: 38797473
[TBL] [Abstract][Full Text] [Related]
9. Interrogating the roles of lymph node metastasis in systemic immune surveillance.
Basto PA; Reticker-Flynn NE
Clin Exp Metastasis; 2024 Feb; ():. PubMed ID: 38315348
[TBL] [Abstract][Full Text] [Related]
10. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
11. Immunological Mechanisms behind Anti-PD-1/PD-L1 Immune Checkpoint Blockade: Intratumoral Reinvigoration or Systemic Induction?
Guo Z; Yu J; Chen Z; Chen S; Wang L
Biomedicines; 2024 Mar; 12(4):. PubMed ID: 38672120
[TBL] [Abstract][Full Text] [Related]
12. Photo-induced crosslinked and anti-PD-L1 peptide incorporated liposomes to promote PD-L1 multivalent binding for effective immune checkpoint blockade therapy.
Lee Y; Song S; Yang S; Kim J; Moon Y; Shim N; Yoon HY; Kim S; Shim MK; Kim K
Acta Pharm Sin B; 2024 Mar; 14(3):1428-1440. PubMed ID: 38487005
[TBL] [Abstract][Full Text] [Related]
13. Liposome-mediated PD-L1 multivalent binding promotes the lysosomal degradation of PD-L1 for T cell-mediated antitumor immunity.
Yang S; Shim MK; Song S; Cho H; Choi J; Jeon SI; Kim WJ; Um W; Park JH; Yoon HY; Kim K
Biomaterials; 2022 Nov; 290():121841. PubMed ID: 36206664
[TBL] [Abstract][Full Text] [Related]
14. All-in-one glycol chitosan nanoparticles for co-delivery of doxorubicin and anti-PD-L1 peptide in cancer immunotherapy.
Song S; Shim MK; Yang S; Lee J; Yun WS; Cho H; Moon Y; Min JY; Han EH; Yoon HY; Kim K
Bioact Mater; 2023 Oct; 28():358-375. PubMed ID: 37334068
[TBL] [Abstract][Full Text] [Related]
15. Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death.
Moon Y; Shim MK; Choi J; Yang S; Kim J; Yun WS; Cho H; Park JY; Kim Y; Seong JK; Kim K
Theranostics; 2022; 12(5):1999-2014. PubMed ID: 35265195
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
